News
13 JUL 2015 | The patent for long-acting recombinant Alpha-1 Antitrypsin (A1AT)
Author
alteogen
Date
2018-05-28 11:31
ALTEOGEN succeeded in registering the patent for long-acting recombinant Alpha-1 Antitrypsin (A1AT) in US.
The patent 'ALPHA-1 ANTITRYPSIN VARIANT, PREPARATION METHOD THEREOF AND USE THEREOF' is for recombinant Alpha-1 Antitrypsin (A1AT) which has three times longer in-vivo halflife compared with plasma derived A1At.
The patent 'ALPHA-1 ANTITRYPSIN VARIANT, PREPARATION METHOD THEREOF AND USE THEREOF' is for recombinant Alpha-1 Antitrypsin (A1AT) which has three times longer in-vivo halflife compared with plasma derived A1At.